These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31556818)

  • 1. Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer.
    Schwartz NRM; Flanagan MR; Babigumira JB; Steuten LM; Roth JA
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1133-1139. PubMed ID: 31556818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Martin M; Holmes FA; Ejlertsen B; Delaloge S; Moy B; Iwata H; von Minckwitz G; Chia SKL; Mansi J; Barrios CH; Gnant M; Tomašević Z; Denduluri N; Šeparović R; Gokmen E; Bashford A; Ruiz Borrego M; Kim SB; Jakobsen EH; Ciceniene A; Inoue K; Overkamp F; Heijns JB; Armstrong AC; Link JS; Joy AA; Bryce R; Wong A; Moran S; Yao B; Xu F; Auerbach A; Buyse M; Chan A;
    Lancet Oncol; 2017 Dec; 18(12):1688-1700. PubMed ID: 29146401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
    Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of six months versus 1-year adjuvant trastuzumab in HER2 positive early breast cancer in Egypt.
    Elsisi GH; Nada Y; Rashad N; Carapinha J; Noor AO; Almasri DM; Zaidy MA; Foad A; Khaled H
    J Med Econ; 2020 Jun; 23(6):575-580. PubMed ID: 32011199
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines.
    Genuino AJ; Chaikledkaew U; Guerrero AM; Reungwetwattana T; Thakkinstian A
    BMC Health Serv Res; 2019 Nov; 19(1):874. PubMed ID: 31752849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis.
    Khoirunnisa SM; Suryanegara FDA; Setiawan D; Postma MJ; de Jong LA
    PLoS One; 2024; 19(5):e0304483. PubMed ID: 38787899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
    Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
    J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
    Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
    Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
    Chan A; Moy B; Mansi J; Ejlertsen B; Holmes FA; Chia S; Iwata H; Gnant M; Loibl S; Barrios CH; Somali I; Smichkoska S; Martinez N; Alonso MG; Link JS; Mayer IA; Cold S; Murillo SM; Senecal F; Inoue K; Ruiz-Borrego M; Hui R; Denduluri N; Patt D; Rugo HS; Johnston SRD; Bryce R; Zhang B; Xu F; Wong A; Martin M;
    Clin Breast Cancer; 2021 Feb; 21(1):80-91.e7. PubMed ID: 33183970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    Liberato NL; Marchetti M; Barosi G
    J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer.
    Iwata H; Masuda N; Kim SB; Inoue K; Rai Y; Fujita T; Chiu J; Ohtani S; Takahashi M; Miyaki T; Lu YS; Xu B; Yap YS; Bustam A; Yao B; Zhang B; Bryce R; Chan A
    Future Oncol; 2019 Jul; 15(21):2489-2501. PubMed ID: 31140297
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial.
    Delaloge S; Cella D; Ye Y; Buyse M; Chan A; Barrios CH; Holmes FA; Mansi J; Iwata H; Ejlertsen B; Moy B; Chia SKL; Gnant M; Smichkoska S; Ciceniene A; Martinez N; Filipović S; Ben-Baruch NE; Joy AA; Langkjer ST; Senecal F; de Boer RH; Moran S; Yao B; Bryce R; Auerbach A; Fallowfield L; Martin M
    Ann Oncol; 2019 Apr; 30(4):567-574. PubMed ID: 30689703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
    Le V; Zhong L; Narsipur N; Hays E; Tran DK; Rosario K; Wilson L
    J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial.
    Takumoto Y; Shiroiwa T; Shimozuma K; Iwata H; Takahashi M; Baba S; Kobayashi K; Hagiwara Y; Kawahara T; Uemura Y; Mukai H; Taira N; Sawaki M
    Clin Drug Investig; 2022 Mar; 42(3):253-262. PubMed ID: 35233755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer.
    Le QA; Bae YH; Kang JH
    Breast Cancer Res Treat; 2016 Oct; 159(3):565-73. PubMed ID: 27572338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.
    Attard CL; Pepper AN; Brown ST; Thompson MF; Thuresson PO; Yunger S; Dent S; Paterson AH; Wells GA
    J Med Econ; 2015 Mar; 18(3):173-88. PubMed ID: 25347449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer.
    Tran PT; Diaby V
    J Manag Care Spec Pharm; 2020 Feb; 26(2):221. PubMed ID: 32011959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Setting Cost-Effectiveness Analysis Comparing Three Therapeutic Schemes of One-Year Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer from the Cyprus NHS Payer Perspective.
    Ioannou SS; Marcou Y; Kakouri E; Talias MA
    Int J Environ Res Public Health; 2020 Jun; 17(12):. PubMed ID: 32560485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer.
    Hajjar A; Ergun MA; Alagoz O; Rampurwala M
    PLoS One; 2019; 14(6):e0217778. PubMed ID: 31166995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.